provides an additional rationale fo

provides an additional rationale for the first use of a
boosted PI when adherence may be a problem. However, NNRTI-based regimens may have
lower pill burdens and provide greater convenience (particularly the fixed-dose regimen of
tenofovir/emtricitabine/efavirenz), and possibly improved lipid profiles, when compared to PIbased
regimens. Although there is less experience with INSTI-based regimens, studies to date
show similar virologic outcomes with raltegravir when compared to efavirenz, when either is
combined with tenofovir and emtricitabine, over 96 weeks of observation (37).